← Back to Clinical Trials
Recruiting NCT05569018

NCT05569018 Efficacy of a Transdiagnostic Group Treatment for Emotional Disorders Applied in Blended Format: a Controlled Study.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05569018
Status Recruiting
Phase
Sponsor Universitat Jaume I
Condition Anxiety Disorders
Study Type INTERVENTIONAL
Enrollment 144 participants
Start Date 2024-11-23
Primary Completion 2027-07

Trial Parameters

Condition Anxiety Disorders
Sponsor Universitat Jaume I
Study Type INTERVENTIONAL
Phase N/A
Enrollment 144
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-11-23
Completion 2027-07
Interventions
Blended group transversal protocol (BLGr-TP)Face-to-face group transversal protocol (FFGr-TP)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study will consist in a randomized controlled clinical trial (RCT) to test the efficacy of a blended group transversal protocol (BLGr-TP) compared to a face-to-face group transversal protocol (FFGr-TP). The main aims of the study are the following: * To analyze the differential efficacy of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders in aspects of clinical measures, as well as in terms of retention and dropout rate and adherence. * To analyze the differential acceptability of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders. In addition, it is intended to carry out a study of mediators and moderators of the efficacy of both interventions. The established hypotheses in relation to the main goals are: * Both treatment modalities (FFGr-TP and BLGr-TP) will achieve improvements in the symptoms of emotional disorders, reflected in the scores of the clinical measures. * The BLGr-TP will show equivalent efficacy to the FFGr-TP. * The BLGr-TP will show an acceptability comparable to the face-to-face protocol. Both modalities will be well valued by the participants. * In both treatment modalities, the changes achieved are expected to be maintained over time (3, 6 and 12 months).

Eligibility Criteria

Inclusion Criteria: * Being 18 years old or more. * DSM-5 (APA, 1013) diagnostic criteria for emotional disorder (panic disorder, agoraphobia, social anxiety disorder, generalized anxiety disorder, major depressive disorder, dysthymia, obsessive-compulsive disorder, non-specified anxiety disorder, non-specified depressive disorder). * Good understanding of Spanish. * Access to the Internet and email address. * Informed consent to participate. Exclusion Criteria: * Diagnosis of a severe mental disorder (psychotic disorder, bipolar disorder, substance and/or alcohol dependence). * High risk of suicide. * Having a serious medical illness or other condition that prevents treatment from being carried out. * Receiving another psychological treatment during the study period. * Changes and/or increases in pharmacological treatment during the study period (a decrease is accepted).

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology